Gayatri Reilly, MD
Retina Specialist · Chevy Chase, MDNPI 1174718456
Payments from drug & device makers
Across 124 payments — averaging $7718.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$942K
- Regeneron$14K
- AbbVie$378
- Genentech USA, Inc.$200
- Regeneron Healthcare Solutions, Inc.$185
- Biotissue Holdings Inc.$148
- plus $997 from 11 others
What the payments were for
- Food & beverage$1,907100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 70 | $941,594 |
| Regeneron | 6 | $13,550 |
| AbbVie(2 entities) | 13 | $378 |
| Genentech USA, Inc. | 10 | $200 |
| Regeneron Healthcare Solutions, Inc. | 5 | $185 |
| Biotissue Holdings Inc. | 1 | $148 |
| Bausch & Lomb Americas Inc. | 1 | $123 |
| Shire North American Group Inc | 1 | $123 |
| Mallinckrodt Hospital Products Inc. | 3 | $118 |
| Sun Pharmaceutical Industries Inc. | 1 | $116 |
| Astellas Pharma US Inc | 4 | $111 |
| Alcon | 1 | $102 |
| Apellis Pharmaceuticals, Inc. | 1 | $98 |
| Eyepoint US, Inc. | 2 | $91 |
| Novartis | 3 | $70 |
| Alimera Sciences, Inc. | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$148
- AmnioGraft$148
- IC-8 Apthera IOL$123
- enVista MX60 IOL$123
- XIIDRA$123
- CEQUA$116
- Clareon$102
How this compares
$957,051 in reported general payments places this provider in the 90th percentile of 47 retina specialist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 72 | $3,729 |
| Ketorolac Tromethamine | 59 | $1,134 |
| Ofloxacin | 50 | $764 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Chevy Chase
- Michael LaiChevy Chase$1.6M
- Brian DoChevy Chase$1.1M
- Richard GarfinkelChevy Chase$16K
- Daniel BerinsteinChevy Chase$1K
- Adam GerstenblithHagerstown$8.6M
- Michael ElmanBaltimore$304K
- Rohit LakhanpalOwings Mills$168K
- Aziz KhanifarSilver Spring$83K
- Joshua LevinsonGreenbelt$67K
- Reginald SandersGreenbelt$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.